Pay in 4 interest-free payments of $5.83 Learn more
Ships within 48 hours · Estimated delivery Aug 3 - Aug 8
Missed Dose: If a patient misses a scheduled injection, they should contact their healthcare provider for advice
Read our editorial policy to learn more
* Store at a temperature not exceeding 30 degrees C
We serve as your neighborhood alternative to the ER, ensuring you receive a precise diagnosis and an effective recovery plan under one roof
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
Important Disclaimer: AOD-9604 is sold for research purposes only and is not FDA-approved for human use
